| Name |
Creator |
Surgical Therapy of Hepatic Colorectal Metastasis
CA Cancer J Clin 1999;49:231-255 Dr. Yuman Fong (Sloan Kettering). This review summarizes data demonstrating the safety and efficacy of liver resection for colorectal metastases. Hepatic resection in appropriately selected patients remains the only potentially curative treatment for patients with such metastases. Recommendations for preoperative patient evaluation, patient selection, adjuvant therapy, and postoperative follow-up are presented. Other surgical modalities utilized in the treatment of unresectable or recurrent hepatic colorectal metastases, including ablative modalities and surgical delivery of regional chemotherapy, are described.
http://www.cancer.org/docroot/pub/content/pub_3_8x_surgical_therapy_of_hepatic_colorectal_metastasis.asp |
altman23
|
Cleveland Clinic Survival Rates
http://www.clevelandclinic.org/quality/08-11/08-11j.htm |
altman23
|
Combination approach to unresectable liver metastases may improve survival
December 11, 2002. Example of study showing survival rates for ablation of liver mets combined with chemo. RFA would probably show similar results to this and is more widely available in the US
http://www.oncolink.com/resources/article.cfm?c=3&s=8&ss=23&Year=2002&Month=12&id=9147 |
altman23
|
Long term survivors (LTS) of metastatic colorectal cancer (MCRC) treated with chemotherapy only
a North Central Cancer Treatment Group (NCCTG) review. ACO Abstract 693 (2002). "We reviewed 30 NCCTG prospective chemotherapy trials in MCRC that enrolled 3,514 pts from 1974 to 1993 to describe the frequency and characteristics of LTS. Histologic proof of MCRC was verified. Overall, 43 of 3,514 pts (1.2%) survived >5 years. Of these, 36 (1.0%) received chemotherapy only and were LTS, the other 7 had salvage surgery. Furthermore, 18 pts overall (0.5%), including 16 pts (0.6%) treated on 5-FU based protocols, are without evidence of disease (NED) or free from progression (FFP) more than 3 years from cessation of last chemotherapy"
http://www.asco.org/asco/ascoMainConstructor/1,1003,_12-002324-00_29-00A-00_18-002002-00_19-00693,00.asp |
altman23
|
Metastatic Colorectal Cancer: Systemic Treatment in the New Millenium
Moffit Cancer Control Journal Article. Gives survival times and response rates for different chemo regimens (Camptosar, Oxaliplatin)
http://www.moffitt.usf.edu/pubs/ccj/index.htm |
altman23
|
Metastatic colorectal cancer
PMID: 12057092 Curr Treat Options Oncol 2001 Dec;2(6):459-71 (Review Article)Long-term disease-free survival can be achieved in 25% to 40% of selected patients who undergo resection of liver or lung metastases. For all other patients, treatment is palliative.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12057092&dopt=Abstract |
altman23
|
Older Patients with Colon Cancer: Is Adjuvant Chemotherapy Safe and Effective?
J Am Geriatr Soc 2003 Apr;51(4):567-569 PMID: 12657083 43% had Stage II and 57% Stage III disease. The 5-year overall survival was 71% for those who received adjuvant therapy, compared with 64% for those untreated (HR for death from any cause = 0.76; 95% CI = 0.68–0.85). The 5-year recurrence-free rate was 69% in treated patients, compared with 58% in untreated patients (HR for recurrence = 0.68; 95% CI = 0.60–0.76). No significant interaction was observed between age and efficacy of treatment
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12657083&dopt=Abstract |
altman23
|
Osteopontin and colon cancer progression
Clin Exp Metastasis 2003;20(1):85-90 PMID: 12650611 Human colon cancer affects nearly 150,000 patients and results in 60,000 deaths in the United States per year. Despite significant advances in the management of the colon cancer patient, little change in survival rates has been appreciated over the past 50 years. Although significant progress has been made in understanding the sequential genetic events leading to the development of cancer, the precise genes and the associated molecular pathways underlying the development of metastatic potential are still poorly understood. Moreover, our enhanced genetic knowledge has had relatively little trickle down effect on our clinical management of this deadly disease
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12650611&dopt=Abstract |
altman23
|
Patterns of failure following curative resection of colorectal liver metastases
Eur J Surg Oncol 2003 Apr;29(3):248-53 PMID: 12657235 CONCLUSION: Despite optimal patient selection and curative resection of colorectal liver metastases, more than a half of the patients developed cancer recurrence within 2 years
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12657235&dopt=Abstract |
altman23
|
Resection Rate and Role of Postoperative Chemotherapy on Survival After Surgery for Colorectal Liver Metastases
Full text paper from 2001
http://www.kmcgs.or.kr/%EC%9E%90%EB%A3%8C/Resection%20rate%20and%20effect%20of%20postoperative%20chemotherapy%20on%20survival.pdf |
altman23
|
The role of adjuvant therapy after liver resection for colorectal cancer metastases.
Clin Colorectal Cancer 2001 Nov;1(3):154-66 Ruo L, DeMatteo RP, Blumgart LH. (from Sloan Kettering) "The purpose of this review is to outline these various strategies and their role in combination with resection of CRC liver metastases. Although improved hepatic disease-free survival has been demonstrated with some strategies, overall survival is minimally affected and recurrence of metastatic disease at distant sites is still a major problem"
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12450428&dopt=Abstract |
altman23
|
